Cargando…

HIV-1 Subtype C, Tenofovir, and the Relationship With Treatment Failure and Drug Resistance

Detalles Bibliográficos
Autores principales:	Günthard, Huldrych F., Scherrer, Alexandra U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Editorial Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079362/ https://www.ncbi.nlm.nih.gov/pubmed/27869617 http://dx.doi.org/10.1093/infdis/jiw214

Ejemplares similares

Editorial Commentary: The Irreversibility of HIV Drug Resistance
por: Kouyos, Roger D., et al.
Publicado: (2015)

Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients
por: Scherrer, Alexandra U., et al.
Publicado: (2012)

Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics
por: Kühnert, Denise, et al.
Publicado: (2018)

Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C
por: Posada-Céspedes, Susana, et al.
Publicado: (2021)

Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure
por: Sendi, Pedram, et al.
Publicado: (2007)

Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds
por: Yang, Wan-Lin, et al.
Publicado: (2015)

Tenofovir Activating Kinases May Impact the Outcome of HIV Treatment and Prevention
por: Topalis, Dimitri, et al.
Publicado: (2015)

High Tenofovir Failure Rates in an Emerging, Non-B Subtype HIV Epidemic
por: Salvana, Edsel Maurice, et al.
Publicado: (2017)

Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel
por: Günthard, Huldrych F, et al.
Publicado: (2019)

Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
por: Yim, Hyung Joon
Publicado: (2016)

Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor–Based Antiretroviral Treatment
por: Pyngottu, Ashima, et al.
Publicado: (2020)

Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis
por: von Braun, Amrei, et al.
Publicado: (2017)

Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya
por: Brooks, Katherine, et al.
Publicado: (2016)

Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis
por: Grant, Robert M., et al.
Publicado: (2015)

HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes
por: Cilento, Maria E., et al.
Publicado: (2023)

Pre-treatment HIV drug resistance testing cost-effectiveness
por: van de Vijver, David AMC, et al.
Publicado: (2020)

Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
por: Lee, Yun Bin, et al.
Publicado: (2017)

High-Throughput Sequencing of Human Immunoglobulin Variable Regions with Subtype Identification
por: Schanz, Merle, et al.
Publicado: (2014)

Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland
por: Shilaih, Mohaned, et al.
Publicado: (2016)

Interplay Between Transmitted and Acquired HIV Type 1 Drug Resistance: Reasons for a Disconnect
por: De Luca, Andrea, et al.
Publicado: (2015)

HIV and Drug-Resistant Subtypes
por: Nastri, Bianca Maria, et al.
Publicado: (2023)

The HIV-1 Non-subtype B Workgroup: An International Collaboration for the Collection and Analysis of HIV-1 Non-subtype B Data
por: Kantor, Rami, et al.
Publicado: (2005)

Mortality from suicide among people living with HIV and the general Swiss population: 1988‐2017
por: Ruffieux, Yann, et al.
Publicado: (2019)

Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018
por: Jaha, Bashkim, et al.
Publicado: (2023)

Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals
por: Shilaih, Mohaned, et al.
Publicado: (2017)

HIV Drug Resistance in Resource-limited Countries: Threat for HIV Elimination
por: Ngo-Giang-Huong, Nicole, et al.
Publicado: (2019)

Disentangling Human Tolerance and Resistance Against HIV
por: Regoes, Roland R., et al.
Publicado: (2014)

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein
por: Hosseinipour, Mina C, et al.
Publicado: (2020)

Minority K65R Variants and Early Failure of Antiretroviral Therapy in HIV-1–infected Eritrean Immigrant
por: Bansal, Vineeta, et al.
Publicado: (2011)

Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection
por: Schmid, Adrian, et al.
Publicado: (2010)

No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom
por: White, Ellen, et al.
Publicado: (2016)

Relevance of Subtype Classification of PSP
por: Chatterjee, Koustav, et al.
Publicado: (2021)

Commentary on PSP Subtypes in India
por: Behari, Madhuri
Publicado: (2021)

HIV drug resistance testing – The quest for Point-of-Care
por: Noguera-Julian, Marc
Publicado: (2019)

Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda
por: Ayitewala, Alisen, et al.
Publicado: (2020)

Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA
por: Michailidis, Eleftherios, et al.
Publicado: (2013)

Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection
por: Hermans, Lucas E, et al.
Publicado: (2022)

Differential Drug Resistance Acquisition in HIV-1 of Subtypes B and C
por: Soares, Esmeralda A.J.M., et al.
Publicado: (2007)

Myasthenia Gravis: Do the Subtypes Matter?
por: Murthy, J. M. K.
Publicado: (2020)

Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
por: Dickson, Sean, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ml1r170cvl55ubp30clbkk4gj7